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Abstract
Background: Emerging evidences proposed that microRNAs are associated with regulation of distinct physio-
pathological processes including development of normal stem cells and carcinogenesis. In this study we aimed to
investigate microRNA profile of cancer stem-like cells (CSLCs) isolated form freshly resected larynx cancer (LCa)
tissue samples.
Methods: CD133 positive (CD133+) stem-like cells were isolated from freshly resected LCa tumor specimens.
MicroRNA profile of 12 pair of CD133+ and CD133− cells was determined using microRNA microarray and
differential expressions of selvected microRNAs were validated by quantitative real time PCR (qRT-PCR).
Results: MicroRNA profiling of CD133+ and CD133− LCa samples with microarray revealed that miR-26b, miR-203,
miR-200c, and miR-363-3p were significantly downregulated and miR-1825 was upregulated in CD133+ larynx
CSLCs. qRT-PCR analysis in a total of 25 CD133+/CD133− sample pairs confirmed the altered expressions of these
five microRNAs. Expressions of miR-26b, miR-200c, and miR-203 were significantly correlated with miR-363-3p, miR-
203, and miR-363-3p expressions, respectively. Furthermore, in silico analysis revealed that these microRNAs target
both cancer and stem-cell associated signaling pathways.
Conclusions: Our results showed that certain microRNAs in CD133+ cells could be used as cancer stem cell
markers. Based on these results, we propose that this panel of microRNAs might carry crucial roles in LCa
pathogenesis through regulating stem cell properties of tumor cells.
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Background
Larynx Cancer (LCa) is an aggressive neoplasm constitut-
ing approximately 1 to 2.5 % of all human cancer cases
worldwide [1–3]. It is known as one of the most common
tumor types of the head and neck region [4]. Despite
notable enhancements in the therapeutic options; treat-
ment outcome, prognosis, and 5-year survival rates for
LCa remained almost unchanged in nearly past two
decades [5, 6]. Therefore, more studies exploring the
underlying mechanisms of LCa pathogenesis are urgently
needed for better understanding of LCa development and
providing more effective treatment strategies.
Emerging evidences propose the idea that a highly
malignant rare subpopulation of tumor cells exhibits
stem cell-like features [7]. This reservoir of stem-like cells
within the bulk tumor is considered as tumor-initiating or
cancer stem-like cells (CSLCs) with their unique capacity
for unlimited self-renewal, multi-lineage differentiation,
and ability for initiation, maintenance, and spread of
tumor [8]. CSLCs has been proven to be present in a var-
iety of tumors including lung, brain, breast, prostate,
colon, ovarian, and head and neck cancers [9, 10] and are
considered as the driving force for tumor relapse, metasta-
sis, and chemo-radioresistance [11–13].
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We recently demonstrated that stem-like cells are highly
enriched in CD133 overexpressing LCa cells, which are
profoundly positive for stem cell markers including SOX2,
OCT4, KLF4 and ABCG2 [14]. Furthermore, several stud-
ies have pointed to certain gene expression signatures
specific to embryonic stem cells in acquisition and main-
tenance of the biological features of CSLCs [15–17]; how-
ever, the underlying mechanisms are not yet completely
understood. Therefore, elucidation of genetic and epigen-
etic circuits regulating the stem cell characteristics of
CSLCs might help understanding the molecular basis of
carcinogenesis.
There is an increasing body of evidence demonstrating
that microRNAs (miRNAs) are associated with regula-
tion of distinct physio-pathological processes including
development of normal stem cells and carcinogenesis
[18, 19]. MiRNAs are 21–25 nucleotides long, endogen-
ously synthesized, noncoding RNAs that are involved in
post-transcriptional gene silencing of target messenger
RNAs (mRNAs) through binding 3′-untranslated re-
gions (3′UTR) [20]. Deregulation of miRNAs has been
linked to several diseases including cancer, where they
can act as oncogenes or tumor suppressors. Recent studies
implied miRNAs as crucial molecular players in cancer
initiation, progression, and metastasis [21–23].
Recently, utilization of Dicer or Dgcr8 knockout mice,
lacking global miRNA processing capability, demonstrated
that cells failed in self-renewal since stem cell specific
markers couldn’t be downregulated. This indicated the
significance of miRNAs in establishing stem cell identity
[24, 25]. Besides, several miRNAs have been proposed to
have direct roles in survival of CSLCs [8, 26, 27].
Therefore, understanding the contribution of miRNAs
in acquisition and maintenance of CSLCs will provide
the opportunity to develop miRNA-based therapeutic
tools [28].
In this study, we investigated genome-wide miRNA
expression profile of laryngeal CSLCs enriched for




This study has been reviewed and approved by an
institutional review board of Istanbul University,
Cerrahpasa Medical School (IRB No: 35697). 25 LCa
tumor tissue specimens were obtained from Department
of Otorhinolaryngology, Cerrahpasa Medical School,
Istanbul University. None of the patients received radio-
therapy, chemotherapy or immunotherapy subsequent
to the surgery. The characteristics of the patients in-
cluding age, gender, T classification and histological
grade were summarized in Table 1. Freshly resected
tumor tissues were collected immediately after the
surgery and processed for CSLCs isolation. Patients
were included into the study upon giving their written
informed consents. We also obtained consent to pub-
lish from the participants.
Cancer stem cell isolation
CD133 positive (CD133+) cells were isolated from freshly
resected and physically/enzymatically dissociated tumor
tissue samples using Magnetic-activated Cell Sorting
(MACS) technique (Miltenyi Biotech, Bergisch Gladbach,
Germany) and “EasySep Positive Selection Human PE
Selection Kit (StemCell Technologies, (Vancouver, BC,
Canada)” following the manufacturer’s protocol. Shortly,
fresh tumor tissue samples were physically minced with
a scalpel and exposed to enzymatic dissociation using
400 μg/ml Collagenase enzyme (GIBCO, New York,
USA) at 37 °C for 3 h. Dissociated cells were filtered
using a 70-μm cell strainer to get a single cell suspen-
sion. Cells were labeled with CD133/2-PE (Miltenyi
Biotech clone AC133) antibody. After magnetic sorting,
CD133 enriched (CD133+) and remaining (CD133−) cell
populations from the same tissue samples were imme-
diately washed and homogenized in “Lysis/Binding Buffer”
of “mirVana miRNA Isolation Kit” (Ambion, Darmstadt,
Germany) for further RNA isolation.
RNA isolation
Total RNA was isolated from CD133+ and CD133− cells
collected from LCa tumor samples using “mirVana
miRNA Isolation Kit” (Ambion, Darmstadt, Germany)
following the manufacturer’s instructions. The purities
and concentrations of RNA samples were determined
spectrophotometrically using NanoDrop ND-2000c
(Thermo Fisher Scientific, Inc., Wilmington, DE).
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MiRNA microarray and data analysis
Genome wide microRNA profiling of 12 pairs of CD133
+and CD133− cell populations collected from 12 tumor
samples were performed using Agilent Human miRNA
Microarray (V19). 100 ng of total RNA from each
sample were labeled with Cy3 by using Agilent miRNA
labeling kit following manufacturer’s instructions.
Labeled RNAs were heat denatured and hybridized to
Agilent 8x15k miRNA microarray V19 comprised of
2006 miRNAs from Sanger miRBase (release 19) at
55 ° C for 20 h. After hybridization, slides were imme-
diately washed and scanned in Agilent Microarray
Scanner with Surescan High Resolution Technology
(Agilent Technologies, Santa Clara, CA). Feature Ex-
traction v10.7.3.1 (Agilent Technologies, CA) software
was used to extract all features of the data obtained
from the scanned images. Data were normalized by
quantile normalization, using Bioconductor 2.10 with R
version 2.15. Tumor samples were profiled on one of
two different Agilent grid designs: Agilent-031181 (four
pairs of CD133+ and CD133− cell populations collected
from four tumor tissue samples) and Agilent-053955
(eight pairs of CD133+ and CD133− cell populations
collected from eight tumor tissue samples); to correct
for inter-platform differences, values were averaged by
probe set, and each patient profile was compared with
its corresponding CD133− profile by paired analysis
(both pairs being represented on the same platform). P
values and fold changes were calculated for each fea-
ture, using log-transformed values and paired t-test by
patient. Differentially expressed miRNAs with P < 0.01
and 1.4-fold change were selected for further confirm-
ation by RT-PCR. Array data have been deposited into
the Gene Expression Omnibus (accession GSE69128).
MiRNA cDNA synthesis and quantitative reverse-
transcription PCR
For the miRNA selection after microarray analysis,
significantly deregulated miRNA probes were listed ac-
cording to their fold changes. Then, top 10 upregulated
and downregulated probes were selected for further lit-
erature search. We investigated the following properties
and statuses for every single microRNA; deregulation in
cancer, deregulation in larynx cancer, deregulation in
head and neck cancers, expression in stem cells, and
functional studies in stem cells. For top 10 upregulated
microRNAs (hsa-miR-197-3p, hsa-miR-574-3p, hsa-miR-
885-5p, hsa-miR-483-3p, hsa-miR-1281, hsa-miR-328,
hsa-miR-4254, hsa-miR-4290, hsa-miR-1825, hsa-miR-
766-3p), we included those have been shown to be
deregulated in cancer, and have either expression data or
functional studies in stem cells. Only hsa-miR-574-3p,
hsa-miR-328, and hsa-miR-1825 met these criteria. For
top 10 downregulated microRNAs (hsa-miR-106b-5p,
hsa-miR-26b-5p, hsa-miR-494, hsa-miR-425-5p, hsa-miR-
363-3p, hsa-miR-15b-5p, hsa-miR-185-5p, hsa-miR-150-
5p, hsa-miR-223-3p, hsa-miR-142-5p), we included those
have been shown to be deregulated in cancer (having no
controversial expression status; some of these microRNAs
have been shown to be upregulated in some cancer types,
whereas, downregulated in other cancer types), and have
either expression data or functional studies in stem cells.
Only hsa-miR-26b-5p, hsa-miR-363-3p, and hsa-miR-223-
3p met these criteria. Besides, we included miR-200c and
miR-203 since they are strongly associated with stemness
and cancer, although these miRNAs are not in the top 10
differentially expressed miRNAs.
To validate the differential expression of miR-26b, miR-
200c, miR-203, miR-223, miR-328, miR-363-3p, 574-3p,
and miR-1825, a total of 25 pairs of CD133+ and CD133−
cell populations collected from 25 tumor samples includ-
ing those used in microarray experiments were studied.
First strand DNA (cDNA) synthesis was carried out with
30 ng of total RNA from each sample using miRNA
specific primers purchased from Applied Biosystems and
“TaqMan MicroRNA Reverse Transcription Kit” accord-
ing to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA). MiRNA expression analysis by quantita-
tive reverse-transcription PCR was carried out using a
Roche LightCycler480-II real-time thermal cycler (Roche,
Switzerland). TaqMan Universal Master Mix and TaqMan
amplification kits (Applied Biosystems, Foster City, CA)
were used. Expression levels of miRNAs in each CD133+
cell population were calculated as compared to CD133
−cells collected from the same tumor tissue sample.
Therefore, expression levels of CD133− cells were fixed
to 1 for every sample. RNU43 was used for normalization
of miRNA expression analyses. Each experiment was per-
formed in duplicate. The relative quantification analysis
was performed by delta-delta-Ct method as described pre-
viously [29].
Statistical analysis
Data were plotted as mean ± standard error of the
mean. Statistical analysis was carried out using two-
sided Student’s t-test. Pearson Correlation test was used
to show the correlation of differentially expressed mRNAs.
A p-value < 0.05 was considered as statistically significant.
MiRWalk 2.0 [30] and miRTarBase [31] in silico tools were
used to estimate the predicted miRNA targets and to
evaluate the validated miRNA targets, respectively. MiR-
Walk 2.0 is a freely accessible archive of predicted and
experimentally verified miRNA-target interactions [30],
whereas miRTarBase is a miRNA-target interactions data-
base, where the collected miRNA-target interactions are
validated experimentally by reporter assay, western blot,
microarray and next-generation sequencing experiments
[31]. In both tools, miRBase IDs were used as inputs.
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MiRWalk 2.0 and miRTarBase provide the gene list of
predicted/validated targets of miRNAs and predicted
gene interactors of miRNAs based on functional assays,
respectively. The number of tumor suppressor and
oncogenic targets of miRNAs were determined using
miRWalk 2.0 tool. While predicting the targets of miR-
NAs, in ‘Step 4: Enriched functional patterns’, oncogene
or tumor suppressor was selected as gene class, and the
results provided the number of tumor suppressor and
oncogenic targets of the specified miRNA. String [32]
tool was utilized to prepare schematic representation of
miRTarBase results. DIANA-miRPath was used for miRNA
pathway analysis web-server [33].
Results
Subject characteristics
Twenty five LCa patients were included in this study to
explore the miRNA expression status of CD133+ larynx
CSLCs and remaining CD133− non-CSLCs. The diagno-
sis of patients has been confirmed histopathologically in
Istanbul University, Cerrahpasa Medical School. All pa-
tients except one were men and their ages ranged from
44 to 84 years (median, 64 years). Histological grades of
tumor specimens were determined according to World
Health Organization classification, which demonstrated
that 9 tumors were grade II and 16 tumors were grade
III. Clinical characteristics of the patients are summa-
rized in Table 1.
MiRNA profile of CD133+ larynx CSLCs
To analyze the global miRNA profile of CD133+ cells iso-
lated from freshly resected LCa specimens, we performed
microarray analysis using a discovery set comprised of 12
CD133+ and 12 CD133− samples. Microarray profiling re-
vealed that 405 probes were differentially expressed with a
p value <0.01 (paired t-test) and with at least 1.4-fold
change. A heat map representation of the deregulated
miRNAs is shown in Fig. 1 (entire set of differentially
expressed miRNAs are provided as a Additional file 1:
Data Set). Among those significantly differentially
expressed miRNAs, five downregulated (miR-26b-5p,
miR-200c-3p, miR-203a, miR-223-3p, miR-363-3p) and
three upregulated (miR-328, miR-574-3p, miR-1825)
miRNAs were selected as a result of detailed literature
search for further confirmation with qRT-PCR.
The qRT-PCR results confirmed that five of the eight
selected miRNAs had a differential expression between
groups: miR-26b, miR-200c, miR-203, miR-363-3p, and
miR-1825 (Fig. 2, p values and fold changes are
provided in Table 2). Among those, miR-26b (Fig. 2a,
b), miR-200c (Fig. 2c, d), miR-203 (Fig. 2e, f ), and miR-
363-3p (Fig. 2g, h) were found to have significantly
reduced expression in CD133+ larynx CSLCs, whereas
miR-1825 (Fig. 2i, j) were validated to have increased
expression in these CD133 enriched LCa cells. How-
ever, expression levels of miR-223-3p, miR-328, and
miR-574-3p were not significantly different between
CD133+ vs. CD133− LCa samples (Additional file 2:
Figure S1, p values and fold changes are provided in
Table 2). Although there was no statistically significant
difference in the expression of miR-328 in CD133+
samples, its expression had a tendency to be elevated in
CD133 enriched cell populations (Additional file 2:
Figure S1C, D, Table 2). We further analyzed these
miRNAs’ expressions with regard to T stage and histo-
logical stage of tumor samples. Results showed that
miR-203 has lower expression in stage III samples com-
pared to stage II tumor samples. Besides, miR-1825 has
a tendency to have increased and miR-363-3p and miR-
203 have a tendency to have decreased expression in
T4 stage tumors compared to early stage tumors,
although not significant. Since, miRNAs work in
combination with each other rather than working indi-
vidually and they operate in overlapping regulatory
networks, demonstration of miRNAs’ correlation might
be considered as indicative for their collaborative func-
tioning in cells [34]. We, therefore, performed correl-
ation analysis for the miRNAs found significantly
deregulated between CD133+ and CD133− cells. To
evaluate their correlation, we used Pearson correlation
analysis, which demonstrated that miR-26b, miR-200c,
and miR-203 expressions were significantly correlated
with miR-363-3p, miR-203, and miR-363-3p expres-
sions, respectively, in CD133+ LCa tissue samples
(Fig. 3).
Fig. 1 Heat-map representation of top differentially expressed
miRNAs (p < 0.01, paired t-test, fold change > 1.4) in CD133+ larynx
CSLCs vs. CD133− larynx tumor cells, across twelve different patients.
Yellow, high fold change in CD133+ patient sample as compared to
its corresponding CD133− paired sample; blue, high fold change in
CD133− sample compared to CD133+ paired sample
Karatas et al. BMC Cancer  (2016) 16:853 Page 4 of 11
Fig. 2 a Relative expression levels of miR-26b in each CD133+ and CD133− sample pairs, and (b) mean relative expression levels miR-26b in CD133+
cells with respect to CD133− cells. c Relative expression levels of miR-200c in each CD133+ and CD133− sample pairs, and (d) mean relative expression
levels miR-200c in CD133+ cells with respect to CD133− cells. e Relative expression levels of miR-203 in each CD133+ and CD133− sample pairs, and (f)
mean relative expression levels miR-203 in CD133+ cells with respect to CD133− cells. g Relative expression levels of miR-363-3p in each CD133+ and
CD133− sample pairs, and (h) mean relative expression levels miR-363-3p in CD133+ cells with respect to CD133− cells. i Relative expression levels of
miR-1825 in each CD133+ and CD133− sample pairs, and j mean relative expression levels miR-1825 in CD133+ cells with respect to CD133− cells
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Relevant biological pathways affected from differentially
expressed miRNAs
To explore the relevant biological pathways, which could
be affected by the differential expression of miR-26b, miR-
200c, miR-203, miR-363-3p, and miR-1825, we utilized
DIANA miRPath v2.0, which revealed that several path-
ways overrepresented with a p-value <0.05, including
cancer pathways (Table 3). Furthermore, miRWalk ana-
lysis showed that 3’UTR of several oncogenes were pre-
dicted to be targeted by miR-26b (202 out of 348
oncogenes), miR-200c (161 out of 348 oncogenes), miR-
203 (216 out of 348 oncogenes), and miR-363-3p (175 out
of 348 oncogenes). In addition, various tumor suppressors
were estimated to be targeted by miR-1825 (29 out of 82
tumor suppressors). As to the analysis of validated targets
of these miRNAs, miRTarBase database analysis revealed
that miR-26b, miR-200c, miR-203, and miR-363-3p, and
miR-1825 cooperatively target stem cell associated signal-
ing pathways like Wnt, Hedgehog, and Notch (Fig. 4).
Taken together, these analyses proposed that differential
expression of miRNAs reported here might deregulate
critical pathways involved in both carcinogenesis and es-
tablishment of CSLCs features.
Discussion
MiRNAs have emerged as an abundant class of small
RNAs implicated in post-transcriptional gene regulation.
Since every single miRNA can potentially target hundreds
of genes, their cooperative and additive regulation have
been postulated to have profound impacts on multiple
pathways simultaneously [35]. In addition to their exten-
sively studied roles in tumor biology, they were also pro-
posed to participate in establishing stem cell associated
features [36]. MiRNA-driven pathways were demonstrated
to be fundamental for oncogenesis as well as acquisition
and maintenance of CSLCs characteristics [37, 38]. How-
ever, currently, little is known about the miRNA expres-
sion profiles of CSLCs. Therefore, there is a need for
comprehensive characterization of the miRNAs that might
be involved in the acquisition and maintenance of stem-
ness properties of CSLCs.
In this study, we enriched for CSLCs using CD133
surface marker, which are previously demonstrated to
have increased potential for self-renewal and multi-lineage
differentiating potency in vivo [39] and display elevated
levels of stemness factors in LCa specimens [14]. We fur-
ther investigated the miRNA profiles in CD133+ CSLCs to
find out differences in miRNA expression that could dis-
tinguish them from their more differentiated progenies.
Our findings identified a set of miRNAs in these cells,
which might present valuable information for a better un-
derstanding of the molecular basis of carcinogenesis and
regulation of cancer stem cell features.
Of the miRNAs investigated here, miR-1825 resides
within 20q11.21 chromosomal region, where has been
reported to be a recurrent gain of function abnormality
in human embryonic stem cells and induced pluripo-
tent stem cells [40–42]. Nguyen et al. reported that
human embryonic stem cells with 20q11.21 amplifica-
tion displayed increased colony forming potential and
decreased apoptosis [43]. Interestingly, 20q11.21 ampli-
fication in human embryonic stem cells resulted in
acquisition of a gene-expression signature enriched for
cancer-associated genes [44]. Recently, miR-1825
expression was reported to be elevated in majority of
prostate cancer samples [45], and its expression was
found to be upregulated in pancreatic cancer tissues in
comparison to normal pancreatic duct [46]. In this
study, we found overexpression of miR-1825 in CD133+
larynx CSLCs and suggest miR-1825 as an important
contributor of carcinogenesis as a result of its dysregu-
lation in CD133+ larynx CSLCs.
Table 2 Fold Changes and p values for miRNAs evaluated with
qRT-PCR









P values lower than 0.05 are indicated as bold
Fig. 3 Scatter plot representation of (a) miR-26b/miR-363-3p, (b) miR-200c/miR-203, (c) miR-203/miR-363-3p expression correlation in CD133+ samples
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On the other hand, miR-363-3p, derived from the
miR-106a-363 cluster on chromosome X, has been pre-
viously reported to be dysregulated in multiple cancers
[47]. Although it acts different in distinct tumors, it has
been demonstrated to behave like a tumor suppressor in
several tumors such as colorectal cancer [47], nasal-type
natural killer/T-cell lymphoma [48], head and neck
squamous cell carcinoma [49], and hepatocellular carcin-
oma [50]. Interestingly, MYC, which has been implicated
in stem cell self-renewal, maintenance of pluripotency,
and control of cell fate decisions as well as carcinogen-
esis [51], was reported to directly bind to promoter of
miR-363-3p and inhibit its expression [50]. MYC was
also found to be destabilized by miR-363-3p through
directly targeting and inhibiting USP28 [50] in hepato-
cellular carcinoma, pointing to a putative role for miR-
363-3p in contribution to carcinogenesis and establish-
ment of stemness features. Furthermore, miR-363-3p
was found to directly target and repress GATA6, which
is a transcription factor enhancing the expression of
LGR5 in colorectal cancer [47]. LGR5, under the regula-
tion of Wnt pathway, was proposed as a stem cell
marker [52, 53] and its expression has been found to be
overexpressed in various cancer tissues [54, 55]. These
findings strengthen the potential role of miR-363-3p as a
CSLCs specific miRNA in larynx pathogenesis. Addition-
ally, miR-363 was reported to be repressed in head and
neck squamous cell carcinoma tissues with lymph node
metastasis and cell lines with increased invasive potential
[49]. Ectopic expression of miR-363-3p decreased in vivo
metastatic capacity of human neuroblastoma cells [56]
and reversed the resistance of the breast cancer cell to
the chemotherapeutic agent cisplatin [57]. Considering
these findings and those of our own study, we suggest
miR-363-3p as a strong candidate for establishment of
stemness of CD133high CSLCs.
MiR-26b expression has been found to be downregu-
lated in tongue [58], nasopharyngeal carcinoma [59],
and oral cancers [60]. Exposure to cigarette smoke, as a
Table 3 Overrepresented pathways, which could be affected by
the differential expression of miR-26b, miR-200c, miR-203,
miR-363-3p, and miR-1825
# KEGG pathway p-value # genes # miRNAs
1. p53 signaling pathway <0,001 17 3
2. Viral carcinogenesis <0,001 33 4
3. Small cell lung cancer 0,002 17 2
4. Chronic myeloid leukemia 0,003 3 2
5. Pathways in cancer 0,005 6 3
6. Hepatitis B 0,009 1 1
7. Prostate cancer 0,018 3 2
8. ECM-receptor interaction 0,019 1 1
9. Glycosaminoglycan biosynthesis -
chondroitin sulfate
0,023 5 1
10. Glioma 0,026 2 2
11. Cell cycle 0,028 3 2
12. ErbB signaling pathway 0,043 2 2
13. Epstein-Barr virus infection 0,044 29 2
Fig. 4 Validated targets of miR-26b, miR-200c, miR-203, and miR-363-3p, and miR-1825 are members of stem cell associated signaling pathways
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major risk factor for LCa, was proposed to cause repres-
sion of miR-26 family members’ expressions in animal
models [61]. Besides, recent findings indicated epigenetic
silencing of miR-26a/b in cancer cells particularly
through aberrant DNA hypermethylation [62, 63]. MiR-
26b also displayed low levels of expression in a human
embryonic stem cell line (HUES-17) and in a colorectal
cancer cell line with a high metastatic potential (LoVo)
[64]. Loss of miR-26b also enhanced migration and inva-
sion in oral squamous cell carcinoma [65]. Additionally,
miR-26b expression in neural stem cells was found to be
induced during their differentiation into neurons in vivo
[66]. MiR-26b was also reported to be overexpressed
during osteogenic differentiation of unrestricted somatic
stem cells, which comprise a rare subpopulation in hu-
man cord blood [67]. We, in the present study, showed
that CD133+ LCa cells possess reduced miR-26b expres-
sion. Given that miR-26b is downregulated in both stem
cells and cancer cells, our findings suggest miR-26b as a
CSLC specific miRNA, whose deregulation might par-
ticipate in oncogenic transformation and maintenance of
stem cell state in larynx CSLCs and as well as others.
MiR-200c and miR-203 have previously been extensively
studied in various contexts, and both miRNAs are associ-
ated with the stemness of normal stem cells and CSLCs.
Loss of miR-200 expression was observed during conver-
sion of immortalized human mammary epithelial cells to a
stem-like phenotype [68]. CSLCs isolated from metastatic
breast tumor tissues also exhibited reduced miR-200 ex-
pression [68]. Besides, miR-200c was found to be strongly
downregulated in Oct3/4, Sox2, and Nanog overexpress-
ing CD133+ ovarian cells [69]. MiR-200c expression was
significantly reduced in ALDH1+/CD44+ cells with cancer
stem cell potency in head and neck squamous cell carcin-
oma [70]. Additionally, miR-200c was reported to repress
epithelial-to-mesenchymal transition through directly
targeting and inhibiting ZEB1 and ZEB2 transcription fac-
tors [71]. As one of the central regulators of epithelial
mesenchymal transition (EMT), abnormal expression of
miR-200c was found to alter several important biological
processes implied in cell–cell contact, cell adhesion and
motility [72]. Interestingly, reduced miR-200c expression
was significantly correlated with recurrence in LCa [73].
As to miR-203, it has been found to be downregulated
in head and neck region cancers including LCa [60, 74,
75]. MiR-203 was found to induce differentiation of nor-
mal epidermal stem cells [76, 77] and its expression was
reported to be inhibited during EMT in stem cell-
enriched cancer cell subpopulation [78]. Lower miR-203
expression was significantly associated with poor differ-
entiation, advanced clinical stages, lymph node metasta-
sis and decreased 5-year overall survival in LCa [79].
Additionally, miR-200c and miR-203 cooperatively in-
hibit stem cell factors’ expressions in both cancer cells
and mouse embryonic stem cells [80]. In this study, we
have found miR-200c and miR-203 to be downregulated
in CD133+ larynx CSLCs, supporting their potential in-
volvement in carcinogenesis as driving forces for tumor
initiation, progression, metastasis, and recurrence. We
here also demonstrated that miR-200c, and miR-203
expressions were significantly correlated with miR-203,
and miR-363-3p expressions, respectively, in CD133+
LCa tissue samples. Correlation of those microRNAs ex-
pressions supports a recent report, which demonstrated
that decreased expressions of miR-200c, miR-363, and
miR-203 were associated with poor prognosis in human
head and neck squamous cell carcinoma [81]. Besides,
coordinated loss of miR-200c and miR-203 has been
found to result in enhanced translation of the multiple
targets and chronic activation of NF-κB, PI3K-Akt, and
Ras-Erk pathways, leading to B cell transformation,
which suggest that collaborative actions of multiple miR-
NAs rather than a single miRNA ensure the robustness
of biological processes [82].
Conclusion
In addition to miR-200c and miR-203, which have been
demonstrated in distinct cancers as having CSLCs spe-
cific deregulation pattern, we propose miR-1825, miR-
363-3p, and miR-26b as specific miRNAs with potential
roles in acquisition and maintenance of stem cell associ-
ated features as well as in contributing to tumor initi-
ation, progression, metastasis, chemoresistance, and
recurrence. However, further detailed investigations are
needed for each of the miRNAs studied here, to eluci-
date their roles in carcinogenesis and establishment of
CSLCs related features.
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and (D) mean relative expression levels miR-328 in CD133+ cells with
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each CD133+ and CD133− sample pairs, and (F) mean relative expression
levels miR-574-3p in CD133+ cells with respect to CD133− cells.
(JPG 392 kb)
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